{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:57:07Z","timestamp":1785603427903,"version":"3.56.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute for Health and Care Research Grant numbers","award":["HTA 16\/145\/01"],"award-info":[{"award-number":["HTA 16\/145\/01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Pilot randomised-controlled trial of nortriptyline and escitalopram compared to placebo for depressive symptoms in people with Parkinson\u2019s disease (PD). Participants with PD and depressive symptoms received either nortriptyline, escitalopram or placebo with assessments at baseline and 8 weeks. Feasibility of the full trial was assessed using recruitment rate, loss to follow up before the 8-week primary endpoint, adherence to trial medication and rate of clinically significant adverse reactions. Intended efficacy outcomes included the BDI-II, Patient Health Questionnaire (PHQ-9), Parkinson Anxiety Scale (PAS), MDS-UPDRS and adverse effects. The aim was to recruit 46 participants to determine feasibility of the full trial. 52 participants were recruited from 24 NHS sites and randomised to nortriptyline (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916), escitalopram (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917) or placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919). However, despite multiple strategies, recruitment took two years, and the study therefore did not reach its feasibility aim. Exploratory analyses showed that at 8 weeks depressive symptoms decreased significantly in all three arms. There was no difference in BDI-II score changes between the nortriptyline or the escitalopram when compared to the placebo arm, but PHQ-9 scores showed a greater reduction compared to placebo with nortriptyline (-3.4, 95% CI -5.75 to -0.95) but not with escitalopram (-1.2, 95% CI -3.54 to -1.17). Persistent Anxiety Scale scores showed a similar pattern (nortriptyline: -2.8, 95% CI -5.5 to -0.01; escitalopram: -2.2, 95% CI -4.9 to 0.05). As the study did not reach its primary aim of feasibility due to recruitment difficulties it did not continue to the full trial. The exploratory results are in keeping with previous studies suggesting a beneficial effect of nortriptyline on symptoms of depression and persistent anxiety. The small sample size however limits conclusions on efficacy and a beneficial effect of escitalopram is not excluded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study dataset is available on ClinicalTrials.gov ID<\/jats:title>\n                    <jats:p>NCT03652870, registered 29 August 2018<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00702-026-03170-8","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:08:31Z","timestamp":1778242111000},"page":"1679-1686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Placebo-controlled three-armed pilot trial of Escitalopram or Nortriptyline for depressive symptoms in Parkinson\u2019s disease (ADepT-PD)"],"prefix":"10.1007","volume":"133","clinical-trial-number":[{"clinical-trial-number":"nct03652870","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Anette","family":"Schrag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Embleton-Thirsk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Serfaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Molloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Whipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"McLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glyn","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"3170_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory of measuring depression. Arch Gen Psychiatry 4:53\u201363","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"3170_CR2","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1007\/s00198-016-3667-7","volume":"27","author":"I Carriere","year":"2016","unstructured":"Carriere I, Farre A, Norton J, Wyart M, Tzourio C, Noize P, Peres K, Fourrier-Reglat A, Ancelin ML (2016) Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort. Osteoporos Int 27(11):3187\u20133195. https:\/\/doi.org\/10.1007\/s00198-016-3667-7","journal-title":"Osteoporos Int"},{"key":"3170_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.nbd.2017.07.007","volume":"106","author":"TJ Collier","year":"2017","unstructured":"Collier TJ, Srivastava KR, Justman C, Grammatopoulous T, Hutter-Paier B, Prokesch M, Havas D, Rochet JC, Liu F, Jock K, de Oliveira P, Stirtz GL, Dettmer U, Sortwell CE, Feany MB, Lansbury P, Lapidus L, Paumier KL (2017) Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. Neurobiol Dis 106:191\u2013204. https:\/\/doi.org\/10.1016\/j.nbd.2017.07.007","journal-title":"Neurobiol Dis"},{"issue":"15","key":"3170_CR4","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s00213-014-3467-8","volume":"231","author":"AA Crawford","year":"2014","unstructured":"Crawford AA, Lewis S, Nutt D, Peters TJ, Cowen P, O\u2019Donovan MC, Wiles N, Lewis G (2014) Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology 231(15):2921\u20132931. https:\/\/doi.org\/10.1007\/s00213-014-3467-8","journal-title":"Psychopharmacology"},{"issue":"6","key":"3170_CR5","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/mds.21966","volume":"23","author":"D Devos","year":"2008","unstructured":"Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, Destee A, Bordet R, Defebvre L (2008) Comparison of desipramine and citalopram treatments for depression in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 23(6):850\u2013857. https:\/\/doi.org\/10.1002\/mds.21966","journal-title":"Mov Disord"},{"issue":"15","key":"3170_CR6","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170","journal-title":"Mov Disord"},{"issue":"10","key":"3170_CR7","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"key":"3170_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jclinepi.2016.03.005","volume":"77","author":"DZ Kounali","year":"2016","unstructured":"Kounali DZ, Button KS, Lewis G, Ades AE (2016) The relative responsiveness of test instruments can be estimated using a meta-analytic approach: an illustration with treatments for depression. J Clin Epidemiol 77:68\u201377. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.03.005","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"3170_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16(9):606\u2013613. https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016009606.x","journal-title":"J Gen Intern Med"},{"issue":"8","key":"3170_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/mds.25919","volume":"29","author":"AF Leentjens","year":"2014","unstructured":"Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P (2014) The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. Mov Disord 29(8):1035\u20131043. https:\/\/doi.org\/10.1002\/mds.25919[doi]","journal-title":"Mov Disord"},{"issue":"10","key":"3170_CR11","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","volume":"72","author":"M Menza","year":"2009","unstructured":"Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A (2009) A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72(10):886\u2013892. https:\/\/doi.org\/10.1212\/01.wnl.0000336340.89821.b3","journal-title":"Neurology"},{"issue":"4","key":"3170_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695\u2013699. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x","journal-title":"J Am Geriatr Soc"},{"key":"3170_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2710.2001.00307.x","volume":"26","author":"MA Pina Latorre","year":"2001","unstructured":"Pina Latorre MA, Modrego PJ, Rodilla F, Catal\u00e1n C, Calvo M (2001) Parkinsonism and Parkinson\u2019s Disease associated with long-term administration of sertraline. J Clin Pharm Ther 26:111\u2013112","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"3170_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mds.21803","volume":"23","author":"JS Reijnders","year":"2008","unstructured":"Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson\u2019s disease. Mov Disord 23(2):183\u2013189","journal-title":"Mov Disord"},{"issue":"16","key":"3170_CR15","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","volume":"78","author":"IH Richard","year":"2012","unstructured":"Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W, Group S-PS (2012) A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78(16):1229\u20131236. https:\/\/doi.org\/10.1212\/WNL.0b013e3182516244","journal-title":"Neurology"},{"issue":"1","key":"3170_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s12883-022-02988-5","volume":"22","author":"A Schrag","year":"2022","unstructured":"Schrag A, Carroll C, Duncan G, Molloy S, Grover L, Hunter R, Brown R, Freemantle N, Whipps J, Serfaty MA, Lewis G (2022) Antidepressants Trial in Parkinson\u2019s Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson\u2019s disease. BMC Neurol 22(1):474. https:\/\/doi.org\/10.1186\/s12883-022-02988-5","journal-title":"BMC Neurol"},{"key":"3170_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/0891988703256053","volume":"16","author":"D Weintraub","year":"2003","unstructured":"Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB (2003) Recognition and treatment of depression in Parkinson\u2019s disease. J Geriatr Psychiatr Neurol 16:178\u2013183","journal-title":"J Geriatr Psychiatr Neurol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03170-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03170-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03170-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:07:33Z","timestamp":1785600453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03170-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3170"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03170-8","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}